로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > BCMA

BCMA

요약

Name:B-cell maturation protein
Target Synonym:B-Cell Maturation Protein,B-Cell Maturation Factor,B Cell Maturation Antigen,CD269 Antigen,Tumor Necrosis Factor Receptor Superfamily Member 17,TNFRSF17,TNFRSF13A,CD269,BCM,BCMA,TNF Receptor Superfamily Member 17,Tumor Necrosis Factor Receptor Superfamily, Member 17,B-Cell Maturation Antigen
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:58
Lastest Research Phase:Approved

제품 리스트 비교 또는 구매

제품번호 제품 설명 구조 순도 특징
EP-127 Human BCMA [Biotinylated] : APRIL Inhibitor Screening Chemiluminescence Assay Kit
EP-118 Human BCMA [Biotinylated] : BAFF Inhibitor Screening Chemiluminescence Assay Kit
BCA-HA2H5 Human APC-Labeled Human BCMA / TNFRSF17 Protein, His Tag (Site-specific conjugation)
BCA-HA2H5-structure
BCA-HA2H4 Human APC-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HA2H4-structure
BCA-HP2H7 Human PE-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HP2H7-structure
BCA-C5257 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Llama IgG2b Fc Tag (MALS verified)
BCA-C5257-structure
BCA-C5257-sds
BCA-HF2H3 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HF2H3-structure
BCA-HF2H3-sds
BCA-C52H3 Canine Canine BCMA / TNFRSF17 Protein,His Tag (MALS verified)
BCA-C52H3-structure
BCA-C52H3-sds
BCA-R52H3 Rat Rat BCMA / TNFRSF17 Protein,His Tag
BCA-R52H3-structure
BCA-R52H3-sds
BCA-R52H4 Rabbit Rabbit BCMA / TNFRSF17 Protein,His Tag
BCA-R52H4-structure
BCA-R52H4-sds
BCA-HP2H2 Human PE-Labeled Human BCMA / TNFRSF17 Protein, His Tag (Site-specific conjugation) DMF Filed
BCA-HP2H2-structure
BCA-C82E5 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, His,Avitag™
BCA-C82E5-structure
BCA-C82E5-sds
BCA-M43 Mouse Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay)
BCA-M43-sds
MBS-K004 Human Human BCMA-coupled Magnetic Beads
BCA-HF2H1 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, His Tag DMF Filed
BCA-HF2H1-structure
BCA-HF2H1-sds
BCA-H5253 Human Human BCMA / TNFRSF17 Protein, Mouse IgG2a Fc Tag, low endotoxin
BCA-H5253-structure
BCA-H5253-sds
BCA-M52H3 Mouse Mouse BCMA / TNFRSF17 Protein, His Tag
BCA-M52H3-structure
BCA-M52H3-sds
BCA-H82E4 Human Biotinylated Human BCMA / TNFRSF17 Protein, His,Avitag™ DMF Filed
BCA-H82E4-structure
BCA-H82E4-sds
BCA-H5259 Human Human BCMA / TNFRSF17 Protein, Llama IgG2b Fc Tag, low endotoxin
BCA-H5259-structure
BCA-H5259-sds
BCA-C52H7 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, His Tag
BCA-C52H7-structure
BCA-C52H7-sds
BCA-M82F0 Mouse Biotinylated Mouse BCMA / TNFRSF17 Protein, Fc,Avitag™
BCA-M82F0-structure
BCA-M82F0-sds
BCA-M5258 Mouse Mouse BCMA / TNFRSF17 Protein, Fc Tag
BCA-M5258-structure
BCA-M5258-sds
BCA-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc Tag
BCA-C5253-structure
BCA-C5253-sds
BCA-C82F4 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc,Avitag™
BCA-C82F4-structure
BCA-C82F4-sds
BC7-H82F0 Human Biotinylated Human BCMA / TNFRSF17 Protein, Fc,Avitag™ DMF Filed
BC7-H82F0-structure
BC7-H82F0-sds
BCA-H522y Human Human BCMA / TNFRSF17 Protein,His Tag (HPLC-verified) DMF Filed
BCA-H522y-structure
BCA-H522y-sds
BCA-H522y-hplc
BCA-HF254 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, Fc Tag DMF Filed
BCA-HF254-structure
BCA-HF254-sds
BC7-H5254 Human Human BCMA / TNFRSF17 Protein, Fc Tag (HPLC verified) DMF Filed
BC7-H5254-structure
BC7-H5254-sds
BC7-H5254-hplc

일부의 생물활성 데이터

BCA-HP2H7-Cell-based assay
Evaluation of CAR expression

5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human BCMA, His Tag (Cat. No. BCA-HP2H7) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).

BCA-M43-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

BCA-H522y-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-Human BCMA MAb (human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 13.0 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

사용자 리뷰

Synonym Name

TNFRSF17,CD269,BCM,BCMA

Background

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

Clinical and Translational Updates

Related Molecule

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ciltacabtagene autoleucel JNJ-4528; LCAR-B38M; JNJ-68284528 Approved Nanjing Legend Biotechnology Co Ltd Carvykti EU Multiple Myeloma Janssen-Cilag International Nv 2022-02-28 Multiple Myeloma Details
Idecabtagene vicleucel bb-2121 Approved Bluebird Bio Abecma Japan Multiple Myeloma Bristol-Myers Squibb Kk 2021-03-26 Multiple Myeloma Details
Belantamab mafodotin GSK-2857916; GSK2857916 Approved Glaxosmithkline Plc BLENREP EU Multiple Myeloma Glaxosmithkline (Ireland) Ltd 2020-08-05 Bone Marrow Neoplasms; Lymphoma, B-Cell; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Plasmablastic Lymphoma; Amyloidosis Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
HBI-0101 HBI-0101 Phase 1 Clinical Hadassah Medical Organization Details
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) Clinical Wuhan Bio-Raid Biotechnology Hematologic Neoplasms Details
BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) Clinical Hebei Senlang Biological Technology Co Ltd Multiple Myeloma Details
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) Phase 1 Clinical Shandong New Time Pharmaceutical Co Ltd Multiple Myeloma Details
BCMA-NKE BCMA-NKE Phase 1 Clinical Bristol-Myers Squibb Company Multiple Myeloma Details
HY-027 HY-027 Phase 1 Clinical Multiple Myeloma Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) Clinical Huazhong University Of Science And Technology Multiple Myeloma Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) Phase 1 Clinical Wuhan Union Hospital, Shengyan Pharmaceutical Technology Multiple Myeloma Details
Ispectamab debotansine CC-99712; BMS-986352; SP-8919 Phase 1 Clinical Celgene Corp Multiple Myeloma Details
ACTR 087/SEA BCMA combination therapy Phase 1 Clinical Unum Therapeutics Multiple Myeloma Details
MCM-998 MCM-998; LXG-250 Phase 1 Clinical Novartis Pharma Ag Multiple Myeloma Details
BCMA-UCART cell therapy (Shanghai Bioray Laboratory) Clinical Multiple Myeloma Details
Humanized CART Directed Against BCMA ARI-0002h Phase 2 Clinical Instituto De Salud Carlos Iii Multiple Myeloma Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Multiple Myeloma Details
Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Multiple Myeloma Details
JWCAR129 JWCAR129; JWCAR-129 Phase 1 Clinical Suzhou Yaomingjunuo Biotechnology Co Ltd Multiple Myeloma Details
GR-1803 GR-1803 Phase 1 Clinical Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd Multiple Myeloma Details
MCARH-125 MCARH-125 Phase 1 Clinical Memorial Sloan Kettering Cancer Center Multiple Myeloma Details
CC-98633 CC-98633 Celgene Corp Details
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) Persongen Biotherapeutics Details
C-4-29 Phase 1 Clinical Chongqing Precision Biotechnology Co Ltd Carcinoma, Renal Cell; Multiple Myeloma Details
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) LCAR-BCX Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Multiple Myeloma Details
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Multiple Myeloma Details
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) Phase 1 Clinical Multiple Myeloma Details
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) CBG-002 CAR-T Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) Phase 1 Clinical Sichuan University Multiple Myeloma Details
EMB-06 EMB-06; EMB06 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Multiple Myeloma Details
Anti-BCMA CAR-NK Cell Therapy (Sichuan Kelun-Biotech) Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Details
CM-336(Connaught Biomedical Technology) CM-336 Phase 2 Clinical Keymed Biosciences Co Ltd Multiple Myeloma Details
BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) Shenzhen University General Hospital Details
IBI-346 IBI-346 Innovent Biologics(Suzhou) Co Ltd Details
CAR-BCMA(Sheba Medical Center) Phase 2 Clinical Sheba Medical Center, Israel Multiple Myeloma Details
MEDI-2228 MEDI-2228 Medimmune Llc Details
LCAR-B4822M LCAR-B4822M Genscript Biotech Corp Details
ACLX-001 ACLX-001 Arcellx Inc Details
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) Asclepius Technology Company Group Details
Pavurutamab AMG-701 Phase 1 Clinical Amgen Inc Multiple Myeloma Details
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) The First Affiliated Hospital Of Nanchang University Details
GC-012F GC-012F Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Lymphoma, Non-Hodgkin Details
Alnuctamab CC-93269; EM-901 Celgene Corp Details
ALLO-715 ALLO-715 Allogene Therapeutics Inc, Cellectis Details
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) Descartes-08 Cartesian Therapeutics Details
C-CAR088 C-CAR088 Cellular Biomedicine (Shanghai) Co Ltd Details
BCMA CAR-T cell therapy (Chongqing Precision Biotech) Chongqing Precision Biotechnology Co Ltd Details
KITE-585 KITE-585 Kite Pharma, National Cancer Institute Details
P-BCMA-101 P-BCMA-101 Poseida Therapeutics Details
AMG-224 AMG-224 Amgen Inc Details
bb-21217 bb-21217 Bluebird Bio, Bristol-Myers Squibb Company Details
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) Hrain Biotechnology Details
PBCAR-269A PBCAR-269A Precision Biosciences Inc Details
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) The First Affiliated Hospital Of Soochow University Details
AUTO-2 AUTO-2; SUB-96123 Autolus Details
SEA-BCMA SEA-BCMA; SGN-BCMA Seattle Genetics Details
Motacabtagene lurevgedleucel CTX-120 Crispr Therapeutics Details
BCMA CAR-T Cells (Pregene) PRG-1801 Phase 1 Clinical Shenzhen Prekin Biopharmaceutical Co Ltd Multiple Myeloma Details
Anti-BCMA/CD19 CAR-T Therapy(University College London) Phase 1 Clinical University College London Multiple Myeloma Details
HDP-101 HDP-101; HDP101-ATAC Phase 2 Clinical Heidelberg Paraproteinemias; Multiple Myeloma Details
Pacanalotamab AMG-420; BI-836909 Phase 1 Clinical Micromet Multiple Myeloma Details
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Multiple Myeloma Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) BCMA-CART Phase 2 Clinical Hrain Biotechnology Co Ltd Multiple Myeloma Details
Azintuxizumab TNB-383B; ABBV-383 Phase 1 Clinical Teneobio, Abbvie Inc Multiple Myeloma Details
Zevorcabtagene Autoleucel CT-053-CARsgen Phase 2 Clinical Carsgen Biomedicine (Shanghai) Co Ltd Multiple Myeloma Details
Anti-BCMA CAR T-cell therapy (Arcellx) CART-ddBCMA Phase 2 Clinical Arcellx Multiple Myeloma Details
Orvacabtagene autoleucel MCARH-171; ET-140; FCARH-143; ET140-CAR; JCARH-125 Phase 2 Clinical Juno Therapeutics Multiple Myeloma Details
OriC-321 OriC-321; Ori-C-321 Phase 1 Clinical Zhejiang University, OriginCell Therapeutics Co Ltd Multiple Myeloma Details
PHE-885 PHE-885 Phase 2 Clinical Novartis Pharma Ag Hematologic Neoplasms; Multiple Myeloma Details
ALLO-605 ALLO-605; ALLO605 Phase 2 Clinical Allogene Therapeutics Inc Multiple Myeloma Details
BCMA TriTAC HPN-217 Phase 1 Clinical Harpoon Therapeutics, Abbvie Inc Multiple Myeloma Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Multiple Myeloma; Lupus Erythematosus, Systemic Details
CART-BCMA MTV-273; CART-BCMA Phase 1 Clinical University Of Pennsylvania Multiple Myeloma Details
Linvoseltamab REGN-5458 Phase 2 Clinical Regeneron Pharmaceuticals Inc Multiple Myeloma; Renal Insufficiency, Chronic Details
REGN-5459 REGN-5459 Phase 2 Clinical Regeneron Pharmaceuticals Inc Multiple Myeloma; Renal Insufficiency, Chronic Details
Elranatamab PF-06863135 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Bone Marrow Neoplasms; Multiple Myeloma Details

This web search service is supported by Google Inc.

totop